Sfoglia per AUTORE
D'AGOSTINO M
Collezione AO Cuneo
Items : 2
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Cuneo
AOU Città della Salute di Torino
Petrucci MT; Gamberi B; Zambello R; Palmas A; de Fabritiis P; Aquino S; Giuliani N; Capra A; D'Agostino M; Patriarca F; Spadano A; Cea M; Ballanti S; Ledda A; Grasso M; Zamagni E; Offidani M; Galli M; Belotti A; Bertamini L; Rota-Scalabrini D; Musto P; Gay F; Corradini P; Cavo M; Boccadoro M;
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. in Pharmaceuticals (Basel, Switzerland) / Pharmaceuticals (Basel). 2020 Dec 29;14(1):20. doi: 10.3390/ph14010020.
2020
AO Cuneo
AOU Città della Salute di Torino
AO Cuneo
AOU Città della Salute di Torino
Bringhen S; Boccadoro M; Castellino A; Celeghini I; Grasso M; D'Agostino M; Bonello F;